Purine-core inhibitors of HSP90 and their use in treating cancer

A pharmaceutical composition comprising, a pharmaceutically acceptable carrier and an effective amount of one or more compounds of Formula I, or a pharmaceutically acceptable salt thereof,

• wherein:
• A is chosen from a substituted or unsubstituted indanone or indone group;
• B is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group;
• R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, or halo;
• L1 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH2)n—(CH2)n—, —(CH2)nC(═O)(CH2)n—, —(CH2)nC(═O)NH(CH2)n—,—(CH2)nNHC(═O)O(CH2)n—, (CH2)nNHC(═O)NH(CH2)n—, —(CH2)nNHC(═S)S(CH2)n—, —(CH2)nOC(═O)S(CH2)n—, —(CH2)nNH(CH2)n—, —(CH2)nO(CH2)n—, —(CH2)nS(CH2)n—, or —(CH2)nNHC(═S)NH(CH2)n—, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, or 8, and wherein each carbon and/or nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR2R3, —NHSO2R4, —NHC(═O)NR2R3, heteroaryl, aryl, cycloalkyl, or a heterocycle;
• R2 and R3 are independently chosen from —H, alkyl, or —C(═O)OR4;
• and
• R4 is a C1-C4 alkyl;
• and
• L2 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH2)n—(CH2)n—, —(CH2)nC(═O)(CH2)n—, —(CH2)nC(═O)NH(CH2)n—, —(CH2)nNHC(═O)O(CH2)n—, —(CH2)nNHC(═O)NH(CH2)n—, —(CH2)nNHC(═S)S(CH2)n—, —(CH2)nC(═O)S(CH2)n—, —(CH2)nNH(CH2)n—, —(CH2)nO(CH2)n—, —(CH2)nS(CH2)n—, or —(CH2)nNHC(═S)NH(CH2)n—, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, or 8, and wherein each carbon and/or nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR2R3, —NHSO2R4,
• —NHC(═O)NR2R3, heteroaryl, aryl, cycloalkyl, and heterocyclic;
• wherein R2 and R3 are independently chosen from —H, alkyl, or —C(═O)0R4;
• and wherein R4 is a C1-C4 alkyl.